October 7, 2007 — At GE Healthcare’s 2007 Media Day, the company discussed developments in its Biosciences Lab, including advanced breast cancer care and pre-symptomatic diagnosis of Alzheimer’s Disease.

Among those developments is “wetware,” diagnostic pharmaceutical agents, protein biomarkers associated with disease and molecular imaging agents for cancer.

The lab is also adding new capabilities to providing diagnostic tools for drug discovery, spearheading new research collaborations with pharmaceutical companies aimed at early-stage discovery of novel imaging for drugs in the pipeline. The goal is to develop diagnostic tools that can help predict a patient’s response to targeted drug therapies for diseases, such as cancer or Alzheimer’s, and enhance their outcome.

For more information: www.gehealthcare.com


Additional Content

News | Women's Health

Oct. 29, 2026 — Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive ...

Time October 30, 2026
arrow
News | Lung Imaging

Oct. 20, 2026 — Optellum has announced that its Virtual Nodule Clinic (VNC) with Lung Cancer Prediction (LCP) AI is ...

Time October 21, 2026
arrow
News | ASTRO

Sept. 9, 2026 — The 2026 American Society for Radiation Oncology (ASTRO) Annual Meeting, will take place Sept. 26 to 30 ...

Time September 11, 2026
arrow
News | Prostate Cancer

Aug. 13, 2026 — Artera has announced the enrollment of the first patient in its DIRECT-AI registry study, marking the ...

Time August 14, 2026
arrow
News | Radiation Oncology

July 16, 2026 — Raidium has announced the U.S. launch of Raidium Read (R.Read), applying its AI-native imaging solution ...

Time July 16, 2026
arrow
Subscribe Now